country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99516

Copy Link Print Information

Biologically Validated

Vulinacimab

(Synonyms: HLX-06)

Customer Review

Based on 1 Customer Validation

Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer.

For research use only. We do not sell to patients.

Purity: 99.40%
CAS No.: 2250342-36-8
Molecular Weight:145.28 kDa

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Vulinacimab Chemical Structure

CAS No.: 2250342-36-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Verified Bioactivity
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

VEGFR-2

All VEGFR Isoforms :

In Vivo

Vulinacimab (25 mg/kg; i.p.; twice a week for 6 weeks) monotherapy has no antitumor activity in A549 xenograft models, but exhibits potent antitumor activity when used in combination with HLX07^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude (male; subcutaneously implanted A549 cells into both side flank to establish a xenograft model)^[1]
Dosage:

25 mg/kg
Administration:

i.p.; twice a week for 6 weeks
Result:

Had no antitumor activity in monotherapy.
Exhibited potent antitumor activity when used in combination with HLX07.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

3791 [NCBI]

Accession

P35968

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized VEGFR-2 Protein, Human (HEK293, His, HY-P70552) can bind Vulinacimab. The EC₅₀ for this effect is 4.326 ng/mL.

Chemical Information

CAS No. 2250342-36-8
Appearance Liquid
Molecular Weight 145.28 kDa
Color Colorless to light yellow
SMILES

[Vulinacimab]
Synonyms

HLX-06
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (257 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Lin PH, et al. Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy. Expert Opin Biol Ther. 2021;21(11):1491-1507. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Biological Activity
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Vulinacimab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

All VEGFR Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Vulinacimab Related Classifications

HY-P99516 Related Classifications